Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program

Wave Life Sciences (NASDAQ:WVE) is one of the 17 biotechnology stocks with more than 50% upside. As of the February 12 closing, consensus sentiment around Wave Life Sciences (NASDAQ:WVE) remained strongly bullish. The stock received coverage from 15 analysts, all of whom assigned Buy ratings. The stock has a projected median 1-year price target of $32.57, implying more than 154% upside. 10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch Pressmaster/Shutterstock.com On Februa ...